Mesa Laboratories has strong cash conversion and a Piotroski F-Score of 8/9, but revenue growth is weak, quarterly earnings are volatile and about 80% of revenue comes from one product line. The analyst target of $106.25 has already been passed (upside of -17.4%), leaving little room.
Thesis pillars
- Product Line Concentration↑Improving
- Weak Revenue Growth→Stable
- Strong Cash Conversion→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Jun 3, 2026
Mesa Laboratories, Inc. (MLAB) Stock Analysis
Breakout setup · Catalyst-Driven edge
Technology · Scientific & Technical Instruments
Hold if already holding. Not a fresh buy at $131.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clinical Genomics consumables (80.0%); Analyst target reached - limited upside remaining.
Mesa Laboratories designs and manufactures life sciences tools and quality control solutions across four segments - Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics - serving pharmaceutical, healthcare and... Read more
Hold if already holding. Not a fresh buy at $131.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clinical Genomics consumables (80.0%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.3/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Mesa Laboratories, Inc.
About Mesa Laboratories, Inc.
Mesa Laboratories operates four segments - Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics - manufacturing life sciences quality-control instruments and consumables at facilities in Colorado, Montana, Germany, Sweden and Arizona. The company generated approximately 8% of fiscal 2026 sales from China and 45% from other non-U.S. countries, primarily Europe, selling through direct sales personnel and independent distributors worldwide.
Mesa earns revenue primarily from consumables - biological, chemical and cleaning indicators, Gyrolab microfluidic discs, MassARRAY chips and panels, and DialyGuard calibration solutions - sold on a routine, repeat-purchase basis alongside higher-ticket, more cyclical hardware such as peptide synthesizers and genetic analysis instruments. Within Clinical Genomics, approximately 80% of revenue comes from consumables, with a single customer representing about 20% of that division's revenue; within Calibration Solutions, the DialyGuard renal-care product line alone accounts for roughly 30% of division revenue and a third of its gross profit. The October 2023 acquisition of GKE GmbH, SAL GmbH and GKE China expanded the Sterilization and Disinfection Control division's chemical-indicator and healthcare-distribution reach across Europe and Asia. The company depends on sole or limited-source suppliers for certain materials in its Biopharmaceutical Development and Calibration Solutions divisions, a dependency it manages by continuously reviewing its supply base.
Show full overview
Mesa's hardware lines carry more cyclical exposure than its consumables franchise: in Biopharmaceutical Development, only about 35% of fiscal 2026 revenue came from routine consumables versus roughly 40% from discretionary hardware purchases, leaving that division more exposed to swings in customers' capital spending budgets than Clinical Genomics or Calibration Solutions, where consumables dominate. A prolonged pullback in biopharmaceutical capital equipment spending - distinct from the steadier, regulation-driven demand for sterilization and calibration consumables - could disproportionately weigh on Biopharmaceutical Development's growth relative to Mesa's other three segments.
See also: Technology · Scientific & Technical Instruments
From Mesa Laboratories, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Mesa Laboratories, Inc.
Latest news
- NEWS Earnings Preview: MLAB to Report Financial Results on August 10 - Moomoo — Moomoo neutral
- NEWS Earnings Preview: MLAB to Report Financial Results on August 10 - moomoo.com — moomoo.com neutral
- NEWS Mesa Laboratories Q1 Earnings Call Highlights - Yahoo Finance — Yahoo Finance neutral
- NEWS Lazard Asset Management LLC Buys New Stake in Mesa Laboratories, Inc. $MLAB - MarketBeat — MarketBeat neutral
- NEWS MESA LABORATORIES Q1 2027 Earnings Preview: Recent $MLAB Insider Trading, Hedge Fund Activity, and More - Quiver Quantit — Quiver Quantitative neutral
Generated 2026-10-29T11:08:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductClinical Genomics consumables80%10-K Item 1: 'Approximately 80% of our Clinical Genomics revenues are from consumables used on a routine basis'
- MEDIUMProductDialyguard product line30%10-K Item 1A: 'Our Dialyguard product line accounts for approximately 30% of the revenues and one-third of gross profit margin associated with our Calibration Solutions division.'
- MEDIUMGeographicother non-U.S. countries45%10-K Item 1A: 'we generated approximately 8% of our sales from operations in China and 45% of our sales from other non-U.S. countries, primarily in Europe'
- LOWCustomersingle customer (Clinical Genomics division)20%10-K Item 1: 'with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026'
- LOWGeographicChina8.0%10-K Item 1A: 'we generated approximately 8% of our sales from operations in China'
Material Events(8-K, last 90d)
- 2026-06-15Item 5.02LOWMesa Laboratories appointed Lyndsey Crennen, Corporate Controller since 2022, as Chief Accounting Officer effective upon entry into her new employment agreement. Internal promotion; no predecessor departure disclosed.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $131.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clinical Genomics consumables (80.0%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $106.25 reached (−19.1%), stop $122.88 (−6.9%), A.R:R -2.8:1. Score 5.3/10, moderate confidence.
Analyst target $106.25 reached (−19.1% from $131.32); no take-profit level is published. Analyst target $106.25 reached (−19.1%), stop $122.88 (−6.9%), A.R:R -2.8:1. Stop-loss: $122.88.
Concentration risk — Product: Clinical Genomics consumables (80.0%); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).
Mesa Laboratories, Inc. trades at a P/E of 154.5 (forward 12.8). TrendMatrix value score: 6.8/10. Verdict: Hold.
8 analysts cover MLAB with a consensus score of 4.1/5. Average price target: $125.
What does Mesa Laboratories, Inc. do?Mesa Laboratories designs and manufactures life sciences tools and quality control solutions across four segments -...
Mesa Laboratories designs and manufactures life sciences tools and quality control solutions across four segments - Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics - serving pharmaceutical, healthcare and medical device customers from manufacturing sites in the U.S., Germany and Sweden. No single customer exceeded 10% of consolidated revenue in fiscal 2026, though Clinical Genomics' largest customer represented about 20% of that division's revenue.